Verrica Pharmaceuticals Inc. (VRCA) Stock Price & Analysis

Verrica Pharmaceuticals Inc. (VRCA) fell 1.12% to USD 5.3 as of September 8, 2026 at 12:47 UTC, according to Nexqual real-time market data.

VRCA last closed at USD 5.3; the session ranged USD 5.26–5.53 on volume of 12,197 shares. Market capitalization is —, with a 52-week range of USD 3.28–9.82 (NCM). Source: Nexqual, September 8, 2026 at 12:47 UTC.

Key Statistics (as of September 8, 2026 at 12:47 UTC)

Technical Analysis (VRCA)

Nexqual's technical model rates VRCA "NEUTRAL" based on 2 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 12:47 UTC.

From Verrica Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)

Key Strengths & Strategy (as disclosed to the SEC)

• With regards to the cantharidin API, we possessed total inventories in a combination of raw cantharidin and GMP API adequate to produce over 17 million additional finished drug product applicators in the United States.
• In March 2024, YCANTH's (VP-102) active pharmaceutical ingredient, or API, received New Chemical Entity (NCE) status and a listing in the Orange Book from the FDA, providing a minimum five years of regulatory exclusivity.
• Our Product: YCANTH (VP-102) for the Treatment of Molluscum YCANTH (VP-102) is the first FDA-approved product for the treatment of molluscum and its API has been characterized as a NCE, with five years of non-patent regulatory exclusivity associated with that designation.
• Our proprietary single-use applicator allows for precise application to each lesion.

Partnerships

• Lytix BioPharma AS In August 2020, we entered into an exclusive license agreement with Lytix pursuant to which we obtained an exclusive worldwide license for certain technology of Lytix to develop VP-315 for use in all malignant and pre-malignant dermatological indications, other than metastatic melanoma and metastatic Merkel cell carcinoma.
• Torii Collaboration and License Agreement In August 2020, we entered into an option agreement with Torii for the development and commercialization of our product candidates for the treatment of molluscum and common warts in Japan, including YCANTH (VP-102), or the Option Agreement.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:47 UTC. This page is informational and not investment advice.